Day: March 30, 2023

Battalion Oil Corporation Announces Fourth Quarter 2022 Financial and Operating Results

Battalion Oil Corporation Announces Fourth Quarter 2022 Financial and Operating Results

HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) — Battalion Oil Corporation (NYSE American: BATL, “Battalion” or the “Company”) today announced financial and operating results for the fourth quarter 2022. Key Highlights Generated full year 2022 sales volumes of 15,438 barrels of oil equivalent per day (“Boe/d”) Year-end 2022 reserves of approximately 92.0 million barrels of oil equivalent (“MMBoe”) with a standardized measure of discounted future net cash flows of approximately $1.5 billion Tenth well of 2022 capital program put online in January 2023 with one of the strongest IP30’s of the program Strengthened hedge book – weighted average strike price on crude oil swaps of $69.17 in 2023, a 36% increase over 2022 average Substantial progress on acid gas treating facility with expectation of being mechanically complete in early April...

Continue reading

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

– Sutro plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with platinum resistant ovarian cancer in the second quarter – – Dr. Anne Borgman joined Sutro as Chief Medical Officer in February 2023 – – Sutro expanded its relationship with Vaxcyte through an option agreement for the development and manufacturing rights for cell-free extract – – As of year-end 2022, Sutro had cash and investments of $302.3 million and shares of Vaxcyte common stock valued at $32.0 million, which together provide a projected cash runway into the second half of 2024– SOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody...

Continue reading

Super League Gaming Announces Fourth Quarter and Full Year 2022 Financial Results

Super League Gaming Announces Fourth Quarter and Full Year 2022 Financial Results

2022 Revenues Increase 69% to a Record $19.7 million SANTA MONICA, Calif., March 30, 2023 (GLOBE NEWSWIRE) — Super League Gaming (Nasdaq: SLGG), a global leader in building immersive entertainment experiences, has released its fourth quarter and full year 2022 financial results in the form of a shareholder letter. The fourth quarter and full year 2022 results are highlighted by continued revenue growth, particularly in advertising and sponsorship revenue. Management Commentary by Chief Executive Officer, Ann Hand: “We are proud to deliver yet another year of strong revenue growth on the back of a record fourth quarter. As traditional advertising dollars shift to where audiences have moved, Super League’s product-market fit has never been stronger. We see continuing business momentum stemming from a strong pipeline of not only larger...

Continue reading

Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023Completed $185.3 million upsized initial public offering SAN FRANCISCO and SHANGHAI, March 30, 2023 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today reported financial results for the fourth quarter and year ended December 31, 2022, and highlighted recent corporate achievements. “The successful completion of our IPO in February 2023 strengthens our financial position to advance GSBR-1290 and carry out our mission to provide oral small molecule medicines to patients with high unmet medical needs,” said Raymond Stevens, Ph.D., CEO...

Continue reading

Lowell Farms Inc. Announces Audited Fourth Quarter and Fiscal Year 2022 Financial and Operational Results

Lowell Farms Inc. Announces Audited Fourth Quarter and Fiscal Year 2022 Financial and Operational Results

SALINAS, Calif., March 30, 2023 (GLOBE NEWSWIRE) — Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California-born vertically integrated cannabis company with advanced production capabilities including cultivation, extraction, manufacturing, and distribution, announces audited revenue and operating results for the fourth quarter and fiscal year (ended December 31, 2022). All figures stated are in US Dollars. Fourth Quarter and Fiscal Year Financial Highlights: Revenue generated for the quarter ended December 31, 2022, was $9.3 million; a decrease of 38% from the fourth quarter last year and a 7% sequential increase from the third quarter of 2022. Revenue for the year ended December 31, 2022 was $43.5 million. Sales of self-grown bulk wholesale products increased 42% sequentially to $2.8 million during the quarter...

Continue reading

Inventronics Announces 2022 Year End Financial Results

Inventronics Announces 2022 Year End Financial Results

CALGARY, Alberta, March 30, 2023 (GLOBE NEWSWIRE) — Inventronics Limited (“Corporation”) (IVX:TSX Venture), a designer and manufacturer of enclosures for the telecommunications, electric transmission, cable television and other industries in North America, today announced its 2022 audited annual and unaudited Q4 financial results. For the year ended December 31, 2022, the Corporation reported net earnings of $2,093,000, or 43.4 cents per share, on revenue of $14,245,000 compared to net earnings of $1,890,000, or 41.0 cents per share, on revenue of $9,985,000 for the 2021 fiscal year. For the three months ended December 31, 2022, the Corporation reported net earnings of $252,000, or 5.2 cents per share, on revenue of $2,739,000 compared to net earnings of $303,000, or 6.6 cents per share, on revenue of $1,951,000, for the same period...

Continue reading

Micron Solutions, Inc. Reports Fourth Quarter and Full Year 2022 Results

Micron Solutions, Inc. Reports Fourth Quarter and Full Year 2022 Results

FITCHBURG, Mass., March 30, 2023 (GLOBE NEWSWIRE) — Micron Solutions, Inc. (OTCQB: MICR) (the “Company”), a diversified contract manufacturing organization, through its wholly-owned subsidiary, Micron Products, Inc., producing highly-engineered, innovative components requiring precision machining and injection molding, announced financial results for its fourth quarter and fiscal year ended December 31, 2022. For the fourth quarter of 2022, the Company reported $5,553,941 in net sales, as compared to $4,374,960 in the fourth quarter of 2021, a 26.9% increase. This increase is due to stronger results in the company’s core medical market. Net loss for the fourth quarter of 2022 was ($222,563) compared to a net loss of ($928,491) in the fourth quarter of 2021. Gross margin increased to 10.8% in the fourth quarter of 2022, compared...

Continue reading

authID Reports Financial and Operating Results for the  Year Ended December 31, 2022

authID Reports Financial and Operating Results for the Year Ended December 31, 2022

Recently appointed executive leadership and Board of Directors set to help Company advance its next stage of market growth. DENVER, March 30, 2023 (GLOBE NEWSWIRE) — authID® [Nasdaq: AUID] a leading provider of secure identity authentication solutions today reported financial and operating results for the year ended December 31, 2022. “I am excited about the strength of authID’s digital identity technology. It delivers the enhanced, non-repudiable authentication needed to protect both workforce and consumer applications against identity fraud and cyberattacks associated with compromised passwords,” said CEO Rhon Daguro. “In 2022, our stellar development team delivered our Verified 3.0 platform, secured a perfect score in testing for ISO Level 2 Biometric Presentation Attack Detection, achieved ISO 27001 Certification for Information...

Continue reading

Molekule Reports Fourth Quarter and Full Year 2022 Financial Results

Molekule Reports Fourth Quarter and Full Year 2022 Financial Results

Introduces Q1 2023 Revenue Guidance of Approximately $8 Million and Full Year Fiscal 2023 Revenue Guidance of Between $60-$70 Million PALM BEACH GARDENS, Fla., March 30, 2023 (GLOBE NEWSWIRE) — Molekule Group, Inc. (“Molekule” or the “Company”) (Nasdaq: MKUL), an emerging leader in air purification technology solutions, systems for healthcare and commercial smart building applications, and individual consumer protection, today reported financial results for the three months and year ended December 31, 2022 (“FY 2022”). Fourth Quarter 2022 Operational Highlights and Recent Developments The Company’s Pūrgo™ air sanitization device received FDA clearance for the elimination of SARS-CoV-2, with additional testing performed to also confirm elimination of influenza and RSV. Completed the acquisition of Molekule, Inc. on January...

Continue reading

IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

All Cohort 1 leukemia patients have maintained durable morphological complete responses (CR) beyond 18 months and up to 2.7 years in an ongoing Phase 1 trial of INB-100 as of December 9, 2022; Updated clinical data to be reported at the EBMT Annual Meeting in April 2023 INB-200 continued to show durable and favorable responses, with ongoing patients extending beyond 1.5 years and 1.2 years progression free through year-end 2022; currently enrolling patients in Cohort 3; Updated clinical data expected in mid-2023 Presented positive proof-of-concept data demonstrating the potential of INB-300, a next-generation gamma-delta T cell CAR technology, to target tumors while sparing healthy tissue; Additional updates to this program to be reported at the AACR Annual Meeting in April 2023 NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) — IN8bio,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.